AI assistant
Sending…
Atea Pharmaceuticals, Inc. — Director's Dealing 2025
Jun 25, 2025
33577_dirs_2025-06-24_3e51f9d3-8067-4518-881a-1e5b305dc30e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2025-06-20
Reporting Person: Berman Howard (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-20 | Stock Option (Right to Buy) | $3.25 | A | 164800 | Acquired | 2035-06-19 | Common Stock (164800) | Direct |
Footnotes
F1: The option vests and becomes exercisable in thirty-six (36) equal monthly installments following June 20, 2025 such that the option is fully vested on June 20, 2028.
More from Atea Pharmaceuticals, Inc.
Proxy Solicitation & Information Statement
2026
Apr 27
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Regulatory Filings
2026
Jan 8
Major Shareholding Notification
2025
Dec 5